PDCD1 and colorectal carcinoma: Recent research on Oxa has highlighted the importance of the immune system in the response to CRC therapy and shown that Oxa combined with anti-PD-1 agents increases PD-L1 expression and tumor-infiltrating PD-1+CD8+ T cells in the tumors of patients with hypermutated CRC [19].